Reduced immune response to SARS-CoV-2 infection in the elderly after 6 months.

老年人感染SARS-CoV-2 6个月后免疫反应降低

阅读:21
OBJECTIVES: To evaluate the immune persistence and cross-immune response of elderly individuals after Omicron BA.5 infections. METHOD: The neutralizing antibodies against WT, BA.5, XBB.1 and EG.5 strains were analyzed. The T/B-cell subsets' responses were tested through intracellular cytokine staining and flow cytometry. RESULTS: The neutralizing antibodies titers against WT and BA.5 strain, remaining high level for at least 6 months, were higher than that of both XBB.1 and EG.5 variants. The neutralizing antibodies of WT, BA.5, XBB.1, and EG.5 strains in the elderly were slightly lower than those in middle-age. The memory B cells decreased rapidly in the elderly, and Tfh, Th17 cells of the elderly continued to increase for only 3 months, while Tfh and Th17 cells increased in the middle-aged for over 6 months. For the elderly, after peptide stimulation, unswitched/switched memory B cells decreased, while double negative B cells displayed higher proliferation. The proportions of both naïve and Temra cells in CD4(+) and CD8(+) T cells declined, whereas those of Tcm and Tem cells elevated. In the meantime, both CD69(+) and CD38(+) T cells decreased, but the frequencies of PD-1(+) and CTLA-4(+) of CD4(+) and CD8(+) T cells showed an increasing trend. The proportions of PD-1(+) and CTLA-4(+) cells also increased in older people with long COVID symptoms at 3m post-infection. CONCLUSIONS: Omicron BA.5 infection induced lower neutralizing antibodies against XBB.1 and EG.5 variant. The decrease of memory B cells, CD69(+) and CD38(+)T cells, as well as the increase of PD-1(+), CTLA-4(+) of CD4(+)/CD8(+)T cells and double negative B cells, indicate that sustained immune responses against BA.5 infection may wane more rapidly in elderly populations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。